Benralizumab for treating severe eosinophilic asthma
Technology appraisal
Summary (source: NICE)
Reference: TA565
Type: Technology appraisal
Published: 6 March 2019
Last updated: 3 September 2019
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Benralizumab for treating severe eosinophilic asthma is technology appraisal TA565, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 6 March 2019. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.